Environmental Risk Factors and Congenital Heart Disease: An Umbrella Review of 165 Systematic Reviews and Meta-Analyses With More Than 120 Million Participants

Tie-Ning Zhang1,2,3, Qi-Jun Wu1,2*, Ya-Shu Liu1,2, Jia-Le Lv1,2, Hui Sun1,2, Qing Chang1,2, Chun-Feng Liu3 and Yu-Hong Zhao1,2*

1Department of Clinical Epidemiology, Shengjing Hospital of China Medical University, Shenyang, China, 2Clinical Research Center, Shengjing Hospital of China Medical University, Shenyang, China, 3Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China

Background: The etiology of congenital heart disease (CHD) has been extensively studied in the past decades. Therefore, it is critical to clarify clear hierarchies of evidence between types of environmental factors and CHD.

Methods: Electronic searches in PubMed, Embase, Web of Science, Cochrane database were conducted from inception to April 20, 2020 for meta-analyses investigating the aforementioned topic.

Results: Overall, 41 studies including a total of 165 meta-analyses of different environmental factors and CHD were examined, covering a wide range of risk factors. The summary random effects estimates were significant at \( P < 0.05 \) in 63 meta-analyses (38%), and 15 associations (9%) were significant at \( P < 10^{-6} \). Of these meta-analyses, eventually one risk factor (severe obesity; relative risk: 1.38, 95% confidence interval: 1.30–1.47) had significant summary associations at \( P < 10^{-6} \), included more than 1,000 cases, had 95% prediction intervals excluding the null value, and were not suggestive of large heterogeneity (\( I^2 < 50\% \)), small-study effects (\( P \)-value for Egger’s test > 0.10), or excess significance (\( P > 0.10 \)). Eight associations (5%) (including maternal lithium exposure, maternal obesity, maternal alcohol consumption, and maternal fever) had results that were significant at \( P < 10^{-6} \), included more than 1,000 cases, and had 95% prediction intervals excluding the null value (highly suggestive).

Conclusion: This umbrella review shows that many environmental factors have substantial evidence in relation to the risk of developing CHD. More and better-designed studies are needed to establish robust evidence between environmental factors and CHD.

Systematic Review Registration: [PROSPERO], identifier [CRD42020193381].

Keywords: congenital heart disease, risk factor, environment, epidemiology, meta-analysis
INTRODUCTION

Congenital heart disease (CHD) is defined as a gross structural abnormality of the heart or great vessels (1), and is the most frequently occurring congenital disorder in newborns and the most frequent cause of infant death from birth defects (2, 3). Birth prevalence of CHD is estimated to be 8 cases per 1,000 live births (ranging from 3 to 10) (2), which translates to 1.35 million infants with CHD per year, globally (4). Several studies showed that CHD affects ∼2 million families in the United States, which is ∼40,000 babies each year in the United States (5–7). Although the etiology of CHD is largely unknown, numerous studies have suggested that the cause of CHD is multifactorial, and both genetic and environmental factors contribute to the development of this disease. In particular, several environmental risk factors, such as maternal factors including obesity and paternal factors including advanced age, are well-accepted major risk factors for CHD in infants. Other reported environmental risk factors mainly include exposure to air pollutants, maternal alcohol consumption, maternal smoking, and maternal exposure to certain drugs during pregnancy (such as antidepressant drugs). However, at present, well-established risk factors for CHD to assist disease prevention are limited.

Numerous meta-analyses and systematic reviews of environmental risk factors associated with CHD have been published. However, to the best of our knowledge, there has been no effort to summarize the evidence from these meta-analyses and systematic reviews, as well as their associated limitations, and thus contribute to better understanding of environmental risk factors for CHD. Therefore, in order to provide an overview of the range and validity of the reported associations of diverse environmental risk factors with CHD in infants, we performed the first umbrella review and summarized the environmental risk factors in previously published meta-analyses and systematic reviews. We assessed the quality and strength of the evidence, evaluated whether there are biases in this evidence and how they manifested, and identified which could be the most robust associations between environmental risk factors and CHD in infants without potential biases.

METHODS

The report of this umbrella review followed the recommendations of the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guideline (8) and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) group (9). Before study selection, the protocol for this review was registered with the International Prospective Register of Systematic Reviews (PROSPERO) as CRD42020193381.

Literature Search and Eligibility Criteria

We conducted computerized literature searches of databases including PubMed, Embase, Web of Science, and the Cochrane database from inception to April 20, 2020 to identify systematic reviews and meta-analyses of epidemiological studies investigating the association between environmental (non-genetic) factors and risk of CHD. The search key words and Medical Subject Heading (MeSH) terms are provided in Supplementary Table 1. We selected potentially relevant articles after title and abstract screening and included eligible articles after full-text review. In addition, the references cited in the retrieved articles were scrutinized by manual search.

Articles were eligible if the authors had performed a systematic search to identify pertinent studies. We included only systematic reviews and meta-analyses of epidemiological studies in humans. We excluded meta-analyses that investigated the association between genetic markers and CHD risk. We also excluded meta-analyses that did not present study specific data [relative risks (RRs), 95% confidence intervals (CIs), and number of cases/controls]. Additionally, studies that examined CHD as a risk factor for other medical conditions or diseases were also excluded. If an article presented separate meta-analyses on more than one eligible exposure factor, these were assessed separately. We did not apply any language restrictions in the selection of eligible studies. When more than one meta-analysis on the same scientific question was eligible, the meta-analysis with the largest number of studies was selected for further analysis, but we conducted sensitivity analyses to assess the concordance of the summary associations (direction, magnitude, and significance) in these duplicate meta-analyses (10).

Data Extraction

From each eligible meta-analysis, data extraction was done independently by two investigators [T-NZ and Y-SL], and in case of discrepancies, the final decision was that of a third investigator [Q-JW]. We retrieved the first author, year of publication, journal, study design, exposure factors and duration, outcomes, and number of studies. For dose-response meta-analyses, we also retrieved drug dosage exposure factors. If a quantitative synthesis was conducted, we also extracted the study-specific risk estimates [risk ratios, odds ratios (ORs), hazard ratios, or incident risk ratios] together with the corresponding CIs and the number of cases and controls in each study for each risk factor.

Risk of Bias Assessment

The authors [T-NZ and Y-SL] independently assessed the methodological quality of qualified systematic reviews and meta-analyses using AMSTAR 2 (A Measurement Tool to Assess Systematic Reviews) (11). Discrepancies were settled through discussion. The instrument has an overall rating of 16 items related to weaknesses in critical domains (11). In addition, AMSTAR 2 rates the methodological quality of reviews as high, moderate, low, or critically low, instead of creating an overall score (11).

Statistical Analysis

Estimation of the summary effect—for each unique meta-analysis, we estimated the summary effect and 95% CIs using both fixed and random effects models (12).

Assessment of heterogeneity—heterogeneity between studies was assessed using I² statistics. When I² exceeds 50 or 75%, heterogeneity is considered large or very large, respectively (13). We also estimated the 95% prediction intervals (95% PIs), which further explained the heterogeneity between studies, and assessed
the uncertainty of expected outcomes in new studies dealing with the same association (14).

Evaluation of small-study effects—We used the regression asymmetry test proposed by Egger and colleagues to assess whether there was evidence of a small-study effect (i.e., whether smaller studies tended to give larger effect size estimates than larger studies) (15, 16). A \( P < 0.10 \) with a more conservative effect in the larger studies is considered evidence of a small-study effect.

Evidence of excess significance bias—We applied the excess statistical significance test, which evaluates whether the observed (O) number of studies with nominally significant results ("positive" studies, \( P < 0.05 \)) is larger than their expected (E) number (17). Two-tailed \( P < 0.10 \) was considered statistically significant. The expected number of statistically significant studies in each meta-analysis was calculated by summing the statistical power estimates for each study, using an algorithm from a non-central t distribution, and the relative risk estimate of the largest study (i.e., the smallest standard error) was set as the plausible effect size (18). The excess significance test was considered positive when \( P < 0.10 \) given that \( O > E \).

Robustness of Evidence
The associations were categorized into strong, highly suggestive, suggestive, or weak according to the following criteria (19): \( P < 10^{-6} \), \( >1,000 \) cases, \( P < 0.05 \) of the largest study in the meta-analysis, \( I^2 < 50\% \), no evidence of small-study effects, no evidence of excess significance bias, the 95% PI excludes the null value for strong evidence; \( P < 10^{-6} \), \( >1,000 \) cases, \( P < 0.05 \) of the largest study in the meta-analysis for highly suggestive evidence; \( P < 10^{-3} \), \( >1,000 \) cases for suggestive evidence; and \( P < 0.05 \) for weak evidence. Non-significant associations were those with \( P > 0.05 \). All analyses were performed using STATA 12.0.

RESULTS
Characteristics of the Meta-Analyses
Overall, 23,874 studies were searched, and 41 studies including a total of 165 meta-analyses were eligible (Figure 1). The characteristics of the 41 studies are shown in Supplementary Table 2. Notably, 73 of 114 articles screened at full text were excluded because of no meta-analyses (\( n = 23 \)), study specific data missing (\( n = 44 \)), not English publications (\( n = 23 \)).

---

**FIGURE 1** | Flowchart of selection of studies for inclusion in umbrella review on environmental factors and CHD.
Zhang et al. Environmental Risk Factors and CHD

The included meta-analyses summarized 1,088 individual study estimates. There were three to 55 study estimates combined per meta-analysis, with a median of five studies. The included studies covered 137 associations between different kinds of environmental factors and CHD, over 1.4 million cases and 128 million subjects in total. The median number of cases and total population in each meta-analysis was 2,167 and 589,785, respectively. A total of 101 meta-analyses had at least 1,000 CHD cases.

The 165 meta-analyses covered a wide range of environmental factors. Notably, 54 (33%) of the 165 meta-analyses studied associations between maternal body mass index (BMI) (underweight, overweight, and obesity) and CHD risk (20–22). Twenty-eight (17%) of the 165 meta-analyses explored the association between maternal exposure to different kinds of drugs and CHD risk (23–40). Additionally, other meta-analyses examined associations of exposure to air pollutants (n = 16) (41), maternal alcohol consumption (n = 13) (42–45), paternal factors (n = 13) (46, 47), maternal smoking (n = 10) (48–50), maternal metal pollution (n = 2) (53, 54), monochorionic twins (n = 4) (55), maternal disease (n = 6) (56), maternal occupational exposure (n = 3) (57), assisted reproductive technology/in-vitro fertilization (n = 5) (58), maternal reproductive history (n = 5) (59), and maternal parity (n = 2) (60).

We performed methodological quality assessments of 41 included studies using the AMSTAR 2 questionnaire, which is a revised instrument based on AMSTAR retaining 10 of the original domains and 16 items in total (Supplementary Figure 1). AMSTAR 2 can assist decision makers in the identification of high quality systematic reviews, including those based on non-randomized studies of healthcare interventions. In our study, one included study (32) was considered to be of high quality, two studies (30, 38) were considered of moderate quality, and the remaining studies were assessed as low quality or critically low quality. This was because these 38 studies had one or more critical flaws [usually in item 2 (32/41, 78%) and item 9 (23/41, 56%)] and several non-critical flaws [usually in item 3 (39/41, 95%) and item 10 (40/41, 98%)].

Summary Effect Size

The meta-analyses of the 137 associations were re-performed using a fixed-effects and random-effects model. The magnitude of the observed summary random effect estimates ranged from 0.57 to 12.5; 72% of the estimates lay between 1.00 and 2.00 (Figure 2). There were 15 associations that were significant at $P < 10^{-6}$ (Supplementary Table 4; Table 1): valproic acid intake, folate intake, lithium exposure (throughout pregnancy/in the first trimester), maternal alcohol consumption, BMI (obesity, moderately obese, and severely obese), obesity as a risk factor for outflow tract defects, obesity as a risk factor for atrial septal defect (ASD), obesity as a risk factor for tetralogy of Fallot (TOF), monochorionic twins (monochorionic twins vs. singletons, monochorionic twins with twin–twin transfusion syndrome (TTTS) vs. singletons, monochorionic twins without TTTS vs. singletons), and maternal fever. Fourteen associations reached $P < 10^{-3}$, and the P-values of 34 associations were <0.05. The P-values of the remaining 74 associations were not significant. The associations that reached statistical significance (63 in total) indicated that different kinds of environmental factors were

![FIGURE 2](https://example.com/FIGURE2.png)  | Association of meta-analysis summary effect sizes with inverse of the variance.
related to CHD, including two protective factors (maternal folate supplement and maternal multivitamin supplement) and other 61 risk factors.

**Heterogeneity**

Twenty-four (15%) meta-analyses had high heterogeneity ($I^2 \geq 50\%$) and 20 (12%) meta-analyses had very high heterogeneity ($I^2 > 75\%$). The meta-analyses with very high heterogeneity examined exposure to a selective serotonin reuptake inhibitor (throughout pregnancy), folate supplement, air pollutants (SO$_2$ and CO as risk factors for ventricular septal defect (VSD), and SO$_2$ as a risk factor for TOF), maternal alcohol consumption, secondhand smoking, underweight (for outflow tract defects), maternal fever (for left obstructive defects), parity number, paternal age, paternal smoking and alcohol consumption. The 95% PI was also calculated to further assess inter-study heterogeneity. Only the 95% PIs of 14 (8%) meta-analyses excluded the null value (**Supplementary Table 4**).

**Small-Study Effects**

Evidence for small-study effects was noted in 16 (10%) meta-analyses by use of the Egger's test with a more conservative effect in the largest studies. Except for those 16 meta-analyses, there was no evidence for the presence of small-study effects for the other 149 meta-analyses according to Egger's test and comparison between the random effects summary estimate and the point estimate of the largest study (**Supplementary Table 4**).

**Excess Significance**

We detected excess significance using the following criteria: $P < 0.1$ and $P > E$. As a result, we reported there were 29 meta-analyses in which the excess significance test was positive.

**Robustness of Evidence**

Of the 165 eligible meta-analyses, 63 (38%) had nominally significant summary associations ($P < 0.05$) according to a random-effects calculation (**Table 1**), which showed these meta-analyses presented at least weak evidence. Furthermore, we explored whether the reported associations between different kinds of environmental factors and CHD were supported by convincingly highly suggestive, suggestive, or weak evidence based on different assessment criteria (**Table 2**). Among all significant associations, only one meta-analysis (2%) was supported by convincing evidence (21). In that study, the authors summarized data on severe obesity during pregnancy and its association with CHD and reported that severe obesity during pregnancy was associated with a higher risk of developing CHD in infants (relative risk 1.38, 95% CI: 1.30–1.47).

Eight meta-analyses (13%) were supported by highly suggestive evidence (20, 21, 42, 51, 56), and they found positive associations for CHD (with maternal lithium exposure including throughout pregnancy and in the first trimester, maternal alcohol consumption, obesity, moderate obesity, and maternal fever), ASD (with obesity), and outflow tract defects (with obesity). In addition, 11 meta-analyses (17%) were supported by suggestive evidence (21, 31, 33, 38, 46, 58, 59) for an association and the remaining 43 meta-analyses (68%) were supported by weak evidence. Notably, two inverse associations were found for CHD with maternal folate supplementation (suggestive evidence) (31) and maternal multivitamin supplementation (weak evidence) (35).

Finally, we also conducted several sensitivity analyses noting the same associations that would satisfy the same criteria but with fewer individual studies. We noticed that the grading of the evidence for CHD with maternal obesity (highly suggestive evidence), SSRI exposure in the first trimester (suggestive evidence), maternal overweight (weak evidence), and maternal smoking (weak evidence) was not changed. There were no meta-analyses with fewer individual studies that got a higher grading of evidence compared with the meta-analyses that included more individual studies.

**DISCUSSION**

**Principal Findings and Possible Explanations**

In this umbrella review, we provide an overview and appraisal of environmental risk factors that have been associated with CHD risk and its related subtypes. Overall, our umbrella review examined 63 risk factors that could influence the development of CHD in infants. Notably, one (severe obesity) (21) of these risk factors was supported by evidence with convincing epidemiological credibility, as expressed by large sample size (>1,000 cases), $P < 10^{-6}$, low heterogeneity ($I^2 < 50\%$), not suggestive of a small-study effect and excess significant bias, and 95% PIs excluding the null value. In addition, we also reported eight associations (including maternal lithium exposure, maternal obesity, maternal alcohol consumption, and maternal fever) that were supported by evidence with highly suggestive epidemiological credibility. Among these studies with convincing and highly suggestive evidence, the summary effect sizes were relatively large for maternal exposure to lithium (RR > 2).

A possible association between different kinds of environmental factors and the development of CHD has long been speculated, aiming for better prevention and reduced morbidity of CHD from maternal and paternal factors. In our study, 63 of 165 (38%) meta-analyses reported significant results, suggesting their potential role in the process of developing CHD. However, among these nominally significant results, we noticed that 17 (27%) associations had high (or very high) heterogeneity, and 32 (51%) associations had a small-study effect and/or excess significance bias. The applied Egger test may give a spurious signal of small-study effects when there is genuinely high between-study heterogeneity (15). Heterogeneity might often be a manifestation of bias in some studies of a meta-analysis but could also emerge from genuine differences between studies (13, 61). Reasons for heterogeneity include the mixture of cohort studies and case-control studies in some of the meta-analyses, differences in individual studies that included different subtypes of CHDs, differences in assessment of maternal exposure period (such as throughout pregnancy vs. in the first trimester), differences in frequency of exposure in control groups, and differences in the follow-up period and
Assessments across the 63 associations of environmental risk factors with CHD.

| Outcomes                        | Sample size (number of cases) | Significance threshold reached (under the random-effects model) | 95% prediction interval rule | Estimate of heterogeneity* | Small-study effects or excess significance bias | Random-effects summary effect size (95% CI) |
|---------------------------------|-------------------------------|---------------------------------------------------------------|-------------------------------|-----------------------------|-----------------------------------------------|--------------------------------------------|
| **Associations supported by convincing evidence** |                               |                                                               |                               |                             |                                               |                                            |
| Severe obesity                  | CHD                           | >1,000                                                        | <10^{-6}                      | Excluding the null value    | Not large                                     | Neither                                    | 1.38 (1.30–1.47)                           |
| **Associations supported by highly suggestive evidence** |                               |                                                               |                               |                             |                                               |                                            |
| Lithium (pregnancy)             | CHD                           | >1,000                                                        | <10^{-6}                      | Excluding the null value    | Not large                                     | Neither                                    | 2.14 (1.67–2.75)                           |
| Lithium (in the first trimester)| CHD                           | >1,000                                                        | <10^{-6}                      | Excluding the null value    | Not large                                     | Neither                                    | 2.16 (1.69–2.75)                           |
| Maternal alcohol consumption    | CHD                           | >1,000                                                        | <10^{-6}                      | Excluding the null value    | Very large                                    | Small-study effects                        | 1.28 (1.17–1.39)                           |
| Obesity                         | CHD                           | >1,000                                                        | <10^{-6}                      | Excluding the null value    | Not large                                     | Excess significance bias                    | 1.18 (1.14–1.22)                           |
| Moderate obesity                | CHD                           | >1,000                                                        | <10^{-6}                      | Excluding the null value    | Not large                                     | Excess significance bias                    | 1.15 (1.09–1.21)                           |
| Obesity                         | Outflow tract defects         | >1,000                                                        | <10^{-6}                      | Excluding the null value    | Not large                                     | Excess significance bias                    | 1.39 (1.26–1.54)                           |
| Obesity                         | ASD                           | >1,000                                                        | <10^{-6}                      | Excluding the null value    | Not large                                     | Excess significance bias                    | 1.38 (1.21–1.57)                           |
| Maternal fever                  | CHD                           | >1,000                                                        | <10^{-6}                      | Excluding the null value    | Not large                                     | Excess significance bias                    | 1.56 (1.31–1.85)                           |
| **Associations supported by suggestive evidence** |                               |                                                               |                               |                             |                                               |                                            |
| SSR1 (in the first trimester)   | CHD                           | >1,000                                                        | <10^{-3}                      | Excluding the null value    | Large                                         | Neither                                    | 1.26 (1.11–1.37)                           |
| Maternal folate supplementation | CHD                           | >1,000                                                        | <10^{-6}                      | Including the null value    | Very large                                    | Neither                                    | 0.72 (0.63–0.89)                           |
| Fluoxetine (pregnancy)          | CHD                           | >1,000                                                        | <10^{-3}                      | Excluding the null value    | Not large                                     | Neither                                    | 1.60 (1.32–1.95)                           |
| Overweight                      | Outflow tract defects         | >1,000                                                        | <10^{-3}                      | Excluding the null value    | Not large                                     | Excess significance bias                    | 1.19 (1.09–1.31)                           |
| Moderate obesity                | ASD                           | >1,000                                                        | <10^{-3}                      | Excluding the null value    | Not large                                     | Excess significance bias                    | 1.26 (1.13–1.40)                           |
| Severe obesity                  | ASD                           | >1,000                                                        | <10^{-3}                      | Excluding the null value    | Not large                                     | Excess significance bias                    | 1.72 (1.35–2.20)                           |
| IVF/intracytoplasmic sperm injection | CHD                           | >1,000                                                        | <10^{-3}                      | Excluding the null value    | Not large                                     | Excess significance bias                    | 1.45 (1.20–1.75)                           |
| Singleton                       | IVF/intracytoplasmic sperm injection | CHD                           | >1,000                                                        | <10^{-3}                      | Excluding the null value    | Not large                                     | 1.55 (1.21–1.99)                           |
| Gravidity number                | CHD                           | >1,000                                                        | <10^{-3}                      | Excluding the null value    | Not large                                     | Small-study effects/excess significance bias | 1.15 (1.08–1.22)                           |
| Paternal age 35–39              | CHD                           | >1,000                                                        | <10^{-3}                      | Excluding the null value    | Not large                                     | Neither                                    | 1.14 (1.06–1.22)                           |
| Paternal smoking                | CHD                           | >1,000                                                        | <10^{-3}                      | Including the null value    | Very large                                    | Neither                                    | 1.42 (1.17–1.74)                           |
| **Associations supported by weak evidence** |                               |                                                               |                               |                             |                                               |                                            |
| Fluoxetine (in the first trimester) | CHD                           | >1,000                                                        | <0.05                        | Excluding the null value    | Not large                                     | Neither                                    | 1.39 (1.12–1.73)                           |
| Paroxetine                      | CHD                           | >1,000                                                        | <0.05                        | Including the null value    | Not large                                     | Neither                                    | 1.25 (1.01–1.54)                           |

(Continued)
| Outcomes                                | Sample size (number of cases) | Significance threshold reached (under the random-effects model) | 95% prediction interval rule | Estimate of heterogeneity* | Small-study effects or excess significance bias | Random-effects summary effect size (95% CI) |
|-----------------------------------------|-------------------------------|---------------------------------------------------------------|-------------------------------|---------------------------|-----------------------------------------------|---------------------------------------------|
| Nitrofurantoin HLHS                     | <1,000                        | <0.05                                                        | Excluding the null value     | Not large                 | Excess significance bias                      | 3.07 (1.59–5.93)                           |
| Fluconazole CHD                         | >1,000                        | <0.05                                                        | Excluding the null value     | Not large                 | Excess significance bias                      | 1.29 (1.05–1.59)                           |
| Valproic acid CHD                       | <1,000                        | <10^{-6}                                                     | Excluding the null value     | Not large                 | Neither                                       | 2.24 (1.65–3.03)                           |
| Multivitamin                            | >1,000                        | <0.05                                                        | Including the null value     | Large                     | Neither                                       | 0.83 (0.70–0.97)                           |
| Oral hormone pregnancy tests            |                               |                                                              |                               |                           |                                               |                                             |
| Air pollution (NO$_2$)                  |                               |                                                              |                               |                           |                                               |                                             |
| Maternal alcohol consumption            |                               |                                                              |                               |                           |                                               |                                             |
| Secondhand smoking TOF                 | >1,000                        | <0.05                                                        | Excluding the null value     | Not large                 | Neither                                       | 1.19 (1.07–1.33)                           |
| Smoking Septal defect                   | >1,000                        | <0.05                                                        | Excluding the null value     | Very large                | Small-study effects                           | 2.10 (1.32–3.35)                           |
| Smoking Cardiovascular/heart defects    | >1,000                        | <0.05                                                        | Excluding the null value     | Large                     | Neither                                       | 1.10 (1.02–1.17)                           |
| Smoking Heart defect                    | >1,000                        | <0.05                                                        | Excluding the null value     | Large                     | Neither                                       | 1.09 (1.00–1.18)                           |
| Overweight CHD                          | >1,000                        | <0.05                                                        | Including the null value     | Large                     | Neither                                       | 1.06 (1.02–1.11)                           |
| Overweight HLHS                         | <1,000                        | <10^{-3}                                                     | Including the null value     | Not large                 | Small-study effects                           | 1.31 (1.08–1.60)                           |
| Moderate obesity HLHS                   | <1,000                        | <10^{-3}                                                     | Excluding the null value     | Not large                 | Excess significance bias                      | 1.54 (1.21–1.95)                           |
| Severe obesity HLHS                     | <1,000                        | <0.05                                                        | Including the null value     | Not large                 | Neither                                       | 1.60 (1.11–2.31)                           |
| Obesity HLDLS                           | <1,000                        | <10^{-3}                                                     | Excluding the null value     | Not large                 | Excess significance bias                      | 1.52 (1.23–1.88)                           |
| Severe obesity TOF                      | <1,000                        | <10^{-6}                                                     | Excluding the null value     | Not large                 | Excess significance bias                      | 1.95 (1.50–2.52)                           |
| Obesity TOF                             | <1,000                        | <0.05                                                        | Excluding the null value     | Not large                 | Neither                                       | 1.27 (1.07–1.51)                           |
| Obesity Conotruncal defects             | >1,000                        | <0.05                                                        | Including the null value     | Not large                 | Neither                                       | 1.23 (1.08–1.40)                           |
| Severe obesity AVSD                     | <1,000                        | <0.05                                                        | Including the null value     | Not large                 | Neither                                       | 1.44 (1.03–2.00)                           |
| Severe obesity VSD                      | >1,000                        | <0.05                                                        | Excluding the null value     | Not large                 | Excess significance bias                      | 1.23 (1.07–1.41)                           |
| Moderate obesity COA                    | <1,000                        | <0.05                                                        | Including the null value     | Not large                 | Neither                                       | 1.29 (1.03–1.61)                           |
| Obesity COA                             | <1,000                        | <0.05                                                        | Including the null value     | Not large                 | Neither                                       | 1.25 (1.02–1.53)                           |
| Obesity All septal anomalies            | >1,000                        | <0.05                                                        | Excluding the null value     | Not large                 | Small-study effects                           | 1.24 (1.04–1.49)                           |
| Chlorination by-products VSD            | <1,000                        | <0.05                                                        | Excluding the null value     | Not large                 | Excess significance bias                      | 1.59 (1.21–2.07)                           |
| Monochorionic twins vs. singletons      | <1,000                        | <10^{-6}                                                     | Excluding the null value     | Not large                 | Excess significance bias                      | 5.88 (4.18–8.28)                           |
| Monochorionic twins with TTTS vs. singletons | <1,000                        | <10^{-6}                                                     | Excluding the null value     | Not large                 | Excess significance bias                      | 12.50 (8.66–18.05)                         |

(Continued)
response rates among cases and controls. Therefore, the reported associations with CHD need to be interpreted with caution, in particular for the meta-analyses in which the heterogeneity is high, the number of included studies is relative small, and small-study effects and excess significance bias are evident.

As for CHD, we noticed that maternal severe obesity was a risk factor (RR: 1.38; 95% CI: 1.30–1.47), which was supported by convincing evidence. Similarly, when we analyzed the association between obesity/moderate obesity and CHD, we also found that obesity and moderate obesity could also become risk factors for CHD, which were supported by highly suggestive evidence. Additionally, obesity could become the risk factor for some specific subtypes of CHD. For example, obesity had a tendency to increase the incidence rate of ASD (RR:1.38; 95% CI: 1.21–1.57) and outflow tract defects (RR:1.39; 95% CI: 1.26–1.54), which were also supported by highly suggestive evidence. What’s more, the associations between obesity (including moderate obesity and severe obesity) and several subtypes of CHD (including hypoplastic left heart syndrome, TOF, coarctation of the aorta, VSD, atrioventricular septal defect, and conotruncal defects) also passed our evaluation as risk factors with evidence of suggestive or weak epidemiological credibility. All aforementioned associations highly suggested obesity as a risk factor in the process of developing CHD, and several potential mechanisms could explain the associations. Increased fat mass, and in particular increased visceral fat mass, is associated with insulin resistance, hyperinsulinemia, lipo- and glucotoxicity, subclinical inflammation, endothelial dysfunction, and oxidative

### TABLE 1 | Continued

| Outcomes | Sample size (number of cases) | Significance threshold reached (under the random-effects model) | 95% prediction interval rule | Estimate of heterogeneity | Small-study effects or excess significance bias | Random-effects summary effect size (95% CI) |
|----------|-----------------------------|-------------------------------------------------|-----------------------------|---------------------------|-----------------------------------------------|------------------------------------------|
| Monochorionic twins without TTTS vs. singletons | CHD | <1,000 | <10^{-6} | Excluding the null value | Not large | Excess significance bias | 5.44 (3.66–8.08) |
| Monochorionic twins with TTTS vs. Monochorionic twins without TTTS CHD | CHD | <1,000 | <10^{-3} | Excluding the null value | Not large | Excess significance bias | 2.40 (1.64–3.51) |
| Maternal fever | VSD | <1,000 | <0.05 | Including the null value | Not large | Neither | 1.34 (1.02–1.78) |
| Maternal fever | Right obstructive defects | <1,000 | <10^{-3} | Excluding the null value | Not large | Small-study effects/excess significance bias | 2.06 (1.47–2.88) |
| Occupational exposure to solvents | CHD | >1,000 | <0.05 | Including the null value | Not large | Neither | 1.31 (1.06–1.63) |
| Gravity (ever vs. nullgravidity) | CHD | >1,000 | <0.05 | Excluding the null value | Large | Neither | 1.18 (1.03–1.34) |
| History of spontaneous abortion | CHD | >1,000 | <0.05 | Including the null value | Not large | Neither | 1.18 (1.07–1.31) |
| History of induced abortion | CHD | >1,000 | <0.05 | Including the null value | Large | Small-study effects | 1.58 (1.12–2.22) |
| Abortion number | CHD | >1,000 | <0.05 | Excluding the null value | Large | Excess significance bias | 1.31 (1.12–1.52) |
| Parity number | CHD | >1,000 | <0.05 | Excluding the null value | Very large | Neither | 1.06 (1.02–1.09) |
| Paternal age ≥40 | CHD | >1,000 | <0.05 | Excluding the null value | Very large | Neither | 1.20 (1.05–1.38) |
| Paternal medium smoking (10–19 cigarettes per day) | CHD | >1,000 | <0.05 | Excluding the null value | Not large | Neither | 1.41 (1.12–1.77) |
| Paternal heavy smoking (≥20 cigarettes per day) | CHD | >1,000 | <0.05 | Including the null value | Very large | Small-study effects | 1.76 (1.10–2.80) |
| Paternal wine drinking | CHD | >1,000 | <0.05 | Including the null value | Very large | Neither | 1.48 (1.05–2.07) |

*Heterogeneity was categorized as not large (I² < 50%), large (I² ≥ 50% but I² ≤ 75%), and very large (I² > 75%).

ASD, atrial septal defect; AVSD, atrioventricular septal defect; CHD, congenital heart disease; COA, coarctation of the aorta; HLHS, hypoplastic left heart syndrome; IVF, in-vitro fertilization; SSRI, selective serotonin reuptake inhibitor; TOF, tetralogy of Fallot; TTTS, twin-twin transfusion syndrome; VSD, ventricular septal defect.
stress (62, 63). These metabolic, inflammatory, and vascular alterations may generate an adverse impact on the development, gene expression, and function of the placenta, and thus become potentially harmful to the embryo. It has also been proposed that maternal obesity may induce epigenetic changes in the embryo with increased risks of impaired renewal of stem cells and increased risk of malformations (64). Besides, diabetes is more common in overweight and obese individuals, and several studies suggested that diabetes may be a significant risk factor for CHD (65). Unfortunately, we did not perform an evaluation of the association between diabetes and CHD because of specific data missing from the meta-analyses. However, diabetes may have a potential role in CHD and needs to be evaluated in future studies.

Considering the number of studies reporting the association between maternal drugs intake and CHDs, our analyses confirmed the associations. We found that several studies

---

**TABLE 2** Summary of evidence grading for meta-analyses associating environmental factors and CHD.

| Criteria used | Decreased risk | Increased risk |
|---------------|----------------|----------------|
| **Convincing (n = 1)** | Statistical significance at $P < 10^{-6}$; >1,000 cases (or >20,000 participants for continuous outcomes); the largest component study reported a significant effect ($P < 0.05$); the 95% prediction interval excluded the null; no large heterogeneity ($I^2 < 50$%); no evidence of small-study effect ($P > 0.10$) and excess significance bias ($P > 0.10$); | None | Severe obesity |
| **Highly suggestive (n = 8)** | Statistical significance at $P < 10^{-6}$; >1,000 cases (or >20,000 participants for continuous outcomes); the largest component study reported a significant effect ($P < 0.05$); | None | CHD outcome: Maternal lithium exposure including throughout pregnancy and in the first trimester; Maternal alcohol consumption; Obesity; Moderate obesity; Maternal fever; Specific subtype of CHD: Obesity (for ASD and outflow tract defects) |
| **Suggestive (n = 11)** | Statistical significance at $P < 10^{-3}$; >1,000 cases (or >20,000 participants for continuous outcomes); | CHD outcome: Maternal folate supplementation | |
| **Weak (n = 43)** | Statistical significance at $P < 0.05$ | CHD outcome: Maternal multivitamin supplementation | |

ASD, atrial septal defect; AVSD, atriopulmonary septal defect; CHD, congenital heart disease; COA, coarctation of the aorta; HLHS, hypoplastic left heart syndrome; IVF, in-vitro fertilization; SSRI, selective serotonin reuptake inhibitor; TOF, tetralogy of Fallot; TTTS, twin–twin transfusion syndrome; VSD, ventricular septal defect.
concentrated on the association between maternal exposure to anti-depressive drugs [including serotonin reuptake inhibitor (SRI) and selective SRI (SSRI) such as paroxetine, and fluoxetine] and CHD. We re-performed the different meta-analyses mainly according to the types of anti-depressive drugs as well as the maternal exposure period. Notably, we failed to get any significant association between total SSRI and CHD risk when the maternal exposure period was throughout pregnancy. However, when we focused on the first trimester of pregnancy, we noticed that maternal exposure to total SSRI could increase the risk of CHD (supported by suggestive evidence). This might be because the first trimester of pregnancy is the most critical period for heart development. Additionally, our studies also confirmed that maternal exposure to several specific SSRIs (paroxetine and fluoxetine) could lead to the development of CHD. Considering the high prescription rate of SSRIs in pregnant women with depression and that SSRIs could cross the placenta, especially since previous research has shown that serotonin and serotonin transporters have a significant role in heart development (66), the safety of SSRIs should be discussed with women especially in the first trimester. Besides SSRIs, our studies also suggested that maternal intake of folate (supported by suggestive evidence) and multivitamins (supported by weak evidence) had protective roles in development of CHD. However, of note is the high heterogeneity in these two associations, and thus further studies are still needed to verify the protective roles of folate and multivitamins for CHD.

Quantitative synthesis showed that lithium exposure at any time during pregnancy was associated with a significantly increased risk of CHD (supported by highly suggestive evidence). Notably, we also performed sensitivity analysis to explore the association between lithium exposure and CHD using the study performed by Munk-Olsen et al. but failed to draw any significant results. This discrepancy could be due to the inclusion of a larger sample size in the study performed by Fornaro et al. \( (n = 15,647) \) (51) than that in the study by Munk-Olsen et al. \( (n = 333) \) (52). Expanding the sample size and strengthening the statistical power could lead to more convincing results, and we believe there is an association between lithium exposure during pregnancy and CHD in infants.

Maternal alcohol consumption (highly suggestive evidence) and smoking (weak evidence) during pregnancy have also received attention as risk factors for CHD. Recently, the health problems caused by alcohol consumption have become of global public health concern. Although the different individual study results on this association are often inconsistent, we re-evaluated this association and reported maternal alcohol consumption could be a risk factor for CHD through analyses including 55 studies, which contained a large number of cases \( (n = 41,747) \). An improved understanding of the association between alcohol consumption and CHD may have important public health implications, and could help guide future health education on alcohol-related health risks during pregnancy. In addition, we observed a positive association between maternal smoking during pregnancy and the risk of CHD. The potential mechanism regarding maternal smoking leading to CHD is that in utero exposure to nicotine could induce fetal hypoxia and elevate fetal blood pressure (67, 68), and the long-term change in blood pressure can influence the function of cardiac muscles and muscle cells in the aorta (69). Furthermore, a previous study also suggested that genetic regulation was involved in the process of development of CHD, which could be influenced in different ways by the mutagens present in tobacco smoke (70, 71).

Maternal fever in the first trimester appeared to have a positive association with risk of CHD (supported by highly suggestive evidence) (56). Considering this inference was based only on case-control studies, it was necessary to note their potential recall bias and influence in the final conclusion. We know that fever is only a clinical symptom. Among the possible etiologies resulting in fever, infection is the most common pathogenesis mainly including viral, bacterial and fungal organisms. The possible explanation for an association between maternal fever and CHD risk may be attributed to teratogen effects of different kinds of organisms.

Besides the maternal factors, we also reported that paternal factors could influence embryo development and lead to CHD. For example, our study suggested that paternal age, paternal smoking, and even paternal alcohol consumption had impacts on CHD in infants (supported by suggestive and weak evidence). As for paternal age, the mechanism behind such an association is suggested to be that advanced paternal age was previously found to be associated with increased DNA mutations and chromosomal aberrations in sperm (72). Genetic changes in sperm associated with advanced paternal age could lead to an increased risk for birth defects in offspring (73). Similarly, nicotine could affect sperm activity greatly and lead to chromosome aberration, which might affect fetal development, and result in the occurrence of cardiac malformations (46, 74). Besides, paternal smoking could induce maternal passive smoking, and thus may influence embryo development.

### Strengths and Limitations

This umbrella review is the first and the most comprehensive systematic review of meta-analyses on environmental factors and CHD risk. Umbrella reviews have the advantage of building on existing meta-analyses, as opposed to performing new meta-analyses from scratch which would require far more resources with unclear advantages. The robustness and the validity of a total of 63 associations were strictly rated based on the assessment results of a series of statistical analyses. Notably, our umbrella review provided a comprehensive understanding between environmental factors and CHD risk in infants.

Several additional limitations should be considered in the interpretation of our findings. First, some of the caveats pertaining to the interpretation of tests for statistical bias and the potential effect of inflation even in the largest studies, are applicable to all umbrella reviews of risk factors, as previously discussed (13, 61). Second, because of some specific missing data (such as unclear total population numbers of each individual study or unclear total cases in meta-analyses), we excluded some meta-analyses (see Supplementary Table 2), which have explored the association between many other environmental factors and CHD in infants. There may be other environmental factors that could impact on development of CHD in infants,
and thus there is a need for future studies. Third, our approach may have missed possible associations that have been published, such as large-scale cohort studies that have not yet been assessed through meta-analyses. This is also the limitation of the methodology of umbrella reviews. Fourth, while we focus on biases such as small-study effects and excess significance bias and other issues including heterogeneity that may have led to false-positive associations, false-negatives are also possible, especially for associations where limited evidence is available. Fifth, AMSTAR-2 found that 38 out of the 41 included meta-analyses studies being of low quality or critically low quality, indicating more studies of high quality are needed in the future. Finally, CHD is a disease that is diagnosed after birth and therefore, some aborted fetuses that may have had CHD would not have been included in the studies. As such, we might have underestimated the influence of each environmental factor on CHD in infants.

CONCLUSION

Our umbrella review provides evidence for 63 associations between environmental factors and CHD in infants. Notably, one (severe obesity) of these risk factors for CHD was supported by evidence with convincing epidemiological credibility, eight risk factors for CHD were supported by highly suggestive evidence, and other risk factors for CHD were supported by suggestive or weak evidence. Data from more studies and an investigation of the sources of heterogeneity are needed to examine the associations between other environmental factors and CHD risk in infants. Although the mechanisms of these risk factors are not well-understood, our study provides evidence for researchers and policy makers, and thus generates public health implications for CHD prevention.

REFERENCES

1. Mitchell SC, Korones SB, Berendes HW. Congenital heart disease in 56,109 births. Incidence and natural history. Circulation. (1971) 43:523–32. doi: 10.1161/01.CIR.43.3.523
2. van der Bom T, Zomer AC, Zwijnderman AH, Meijboom FJ, Bouma BJ, Mulder BJ. The changing epidemiology of congenital heart disease. Nat Rev Cardiol. (2011) 8:50–60. doi: 10.1038/nrcardio.2010.166
3. Tennant PW, Pearce MS, Bythell M, Rankin J. 20-year survival of children born with congenital anomalies: a population-based study. Lancet. (2010) 375:649–56. doi: 10.1016/S0140-6736(09)61922-X
4. van der Linde D, Konings EE, Slager MA, Helsen WA, Takkenberg JJ, et al. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J Am Coll Cardiol. (2011) 58:2241–7. doi: 10.1016/j.jacc.2011.08.025
5. Marelli A, Gilboa S, Devine O, Kucik J, Ionescu-Ittu R, Rister M, et al. Estimating the congenital heart disease population in the United States in 2010—what are the numbers? J Am Coll Cardiol. (2012) 59:S787. doi: 10.1016/S0735-1097(12)60788-8
6. Reller MD, Strickland MJ, Richelle-Colorusso T, Mahle WT, Correa A. Prevalence of congenital heart defects in metropolitan Atlanta, 1998–2005. J Pediatr. (2008) 153:807–13. doi: 10.1016/j.jpeds.2008.05.059
7. Hoffman JL, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. (2002) 39:1890–900. doi: 10.1016/S0735-1097(02)01886-7

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

AUTHOR CONTRIBUTIONS

T-NZ, Q-JW, and Y-HZ conceived the study and contributed to the design. T-NZ, Y-SL, and J-LL conducted the literature search, literature screening, and extracted the data. Q-JW and HS performed the statistical analysis. T-NZ and Q-JW wrote the first draft of the paper. Y-HZ is the guarantor. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria were omitted. All authors interpreted the data, read the manuscript, and approved the final version.

FUNDING

This work was supported by National Key R&D Program of China (No. 2017YFC0907403 to Y-HZ), the LiaoNing Revitalization Talents Program (No. XLYC1907102 to Q-JW) and No. XLYC1802095 to Y-HZ), and 345 Talent Project to Q-JW.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2021.640729/full#supplementary-material

11
12. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. (2011) 343:d4002. doi: 10.1136/bmj.d4002
13. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. (1997) 315:629–34. doi: 10.1136/bmj.315.7109.629
14. Ioannidis JP, Trikalinos TA. An exploratory test for an excess of significant findings. Clin Trials. (2007) 4:245–53. doi: 10.1177/1740774507079441
15. Tsilidis KK, Papatheodorou SI, Evangelou E, Ioannidis JP. Evaluation of excess statistical significance in meta-analyses of 98 biomarker associations with cancer risk. J Natl Cancer Inst. (2012) 104:1867–78. doi: 10.1093/jnci/djs437
16. Kalliala I, Markozannes G, Gunter MJ, Paraskevaidis E, Gabra H, Mitra A, et al. Obesity and gynaecological and obstetric conditions: umbrella review of the literature. BMJ. (2017) 359:j4531. doi: 10.1136/bmj.j4531
17. Zhu Y, Chen Y, Feng Y, Yu D, Mo X. Association between maternal body mass index and congenital heart defects in infants: a meta-analysis. Congenit Heart Dis. (2018) 13:271–81. doi: 10.1111/chd.12567
18. Cai GJ, Sun XX, Zhang L, Hong Q. Association between maternal body mass index and congenital heart defects in offspring: a systematic review. Am J Obstet Gynecol. (2014) 211:91–100. doi: 10.1016/j.ajog.2014.03.028
19. Stothard KJ, Tennant PW, Bell R, Rankin J. Maternal overweight and obesity and the risk of congenital anomalies: a systematic review and meta-analysis. JAMA. (2009) 301:636–50. doi: 10.1001/jama.2009.113
20. Pelaez-Garcia D, Alcantara-Hernandez N, Abdullahi M. Increasing the risk of spontaneous abortion and major malformations in newborns following use of serotonin reuptake inhibitors during pregnancy: a systematic review and updated meta-analysis. Daru. (2012) 20:75. doi: 10.1186/2008-2231-20-75
21. Rahimi R, Nikfar S, Abbodalli M. Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials. Reprod Toxicol. (2006) 22:571–5. doi: 10.1016/j.reprotox.2006.03.019
22. Painuly N, Painuly R, Heun R, Sharan P. Risk of cardiovascular malformations after exposure to paroxetine in pregnancy. Psychiatry. (2013) 37:198–203. doi: 10.1192/pp.bp.111.039515
23. Goldberg O, Moretti M, Levy A, Koren G. Exposure to nitrofurantoin during early pregnancy and congenital malformations: a systematic review and meta-analysis. J Obstet Gynaecol Can. (2015) 37:150–6. doi: 10.1016/S1701-2163(15)30337-6
24. Brecken MB. Oral contraception and congenital malformations in offspring: a meta-analysis and review of the prospective studies. Obstet Gynecol. (1990) 76:552–7.
25. Grigoriadis S, Graves L, Peer M, Mamaisilavi L, Dennis CL, Vigod SN, et al. Benzodiazepine use during pregnancy alone or in combination with an antidepressant and congenital malformations: systematic review and meta-analysis. J Clin Psychiatry. (2019) 80:12412. doi: 10.4088/JCP.18r12412
26. Alsad AM, Kaplan YC, Koren G. Exposure to fluconazole and risk of congenital malformations in the offspring: a systematic review and meta-analysis. J Obstet Gynaecol Can. (2015) 37:52–67. doi: 10.1016/S1701-2163(15)30037-6
27. Tanoshima M, Kobayashi T, Tanoshima R, Beyene J, Koren G, Ito S. Risks of congenital malformations in offspring exposed to valproic acid in utero: a systematic review and cumulative meta-analysis. Clin Pharmacol Ther. (2015) 98:417–41. doi: 10.1002/cpt.158
28. Feng Y, Wang S, Chen R, Tong X, Wu Z, Mo X. Maternal folic acid supplementation and the risk of congenital heart defects in offspring: a meta-analysis of epidemiological observational studies. Sci Rep. (2015) 5:8506. doi: 10.1038/srep08506
29. De-Regil LM, Peña-Rosas JP, Fernández-Gaxiola AC, Rayco-Solón P. Effects and safety of periconceptional oral folate supplementation for preventing birth defects. Cochrane Database Syst Rev. (2015) 12:CD007790. doi: 10.1002/14651858.CD007790.pub3
30. Riggin L, Frankel Z, Moretti M, Pupco A, Koren G. The fetal safety of fluoxetine: a systematic review and meta-analysis. J Obstet Gynaecol Can. (2013) 35:362–9. doi: 10.1016/S1701-2163(13)30965-8
31. Selmer R, Haglund B, Furu K, Andersen M, Norgaard M, Zoega H, et al. Individual-based versus aggregate meta-analysis in multi-database studies of pregnancy outcomes: the Nordic example of selective serotonin reuptake inhibitors and venlafaxine in pregnancy. Pharmacoepidemiol Drug Saf. (2015) 24:1160–9. doi: 10.1002/pds.4033
32. Gao SY, Wu QJ, Zhang TN, Shen ZQ, Liu CX, et al. Use of selective serotonin-reuptake inhibitors in the first trimester and risk of cardiovascular-related malformations: a meta-analysis of cohort studies. Sci Rep. (2017) 7:43085. doi: 10.1038/srep43085
33. Peng J, Meng Z, Wang L, Yang T, Chen L, Zhao L, Wang T, et al. Parental alcohol consumption and the risk of congenital heart diseases in offspring: an updated systematic review and meta-analysis. Eur J Preventive Cardiol. (2020) 7:410–21. doi: 10.1177/2047487318745300
34. Chen EK, Zmirou-Navier D, Padilla C, Deguen S. Effects of air pollution on the risk of congenital anomalies: a systematic review and meta-analysis. Int J Environ Res Public Health. (2014) 11:7642–68. doi: 10.3390/ijerph110807642
35. Zhang S, Wang L, Yang T, Chen L, Zhao L, Wang T, et al. Parental alcohol consumption before and during pregnancy and the risks of congenital heart defects in offspring: a systematic review and meta-analysis. Congenit Heart Dis. (2015) 10:E216–24. doi: 10.1111/chd.12271
36. Yang J, Qiu H, Qu P, Zhang R, Zeng L, Yan H. Prenatal alcohol exposure and congenital heart defects: a meta-analysis. PLoS ONE. (2015) 10:e130681. doi: 10.1371/journal.pone.0130681
37. Peng J, Meng Z, Zhou S, Zhou Y, Wu Y, Wang Q, et al. The non-genetic paternal factors for congenital heart defects: a systematic review and meta-analysis. Clin Cardiol. (2016) 42:684–91. doi: 10.1111/ccd.123194
38. Sun J, Chen X, Chen H, Ma Z, Zhou J. Maternal alcohol consumption before and during pregnancy and the risks of congenital heart defects in offspring: a systematic review and meta-analysis. Congenit Heart Dis. (2015) 10:E216–24. doi: 10.1111/chd.12271
39. Zheng Z, Xie G, Yang T, Qin J. Congenital malformations are associated with secondhand smoke among non-smoking women: a meta-analysis. Birth-Issues Perinatal Care. (2019) 46:222–33. doi: 10.1111/birt.12401
40. Zhang D, Cui H, Zhang L, Huang Y, Zhu J, Li X. Is maternal smoking during pregnancy associated with an increased risk of congenital heart defects among offspring? A systematic review and meta-analysis of observational studies. J Matern Fetal Neonatal Med. (2017) 30:645–57. doi: 10.1080/14767058.2016.1183640
41. Hackshaw A, Rodeck C, Boniface S. Maternal smoking in pregnancy and birth defects: a systematic review based on 173 687 malformed cases and 11.7 million controls. Hum Reprod Update. (2018) 24:320–89. doi: 10.1093/humupd/dmy005
42. Fornaro M, Maritan E, Ferriani R, Zaninotto L, Miola A, Anastasia A, et al. Lithium exposure during pregnancy and the postpartum period: a systematic review and meta-analysis of safety and efficacy outcomes. Am J Psychiatry. (2020) 177:776–92. doi: 10.1176/appi.ajp.2019.19030228
43. Munk-Olsen T, Liu X, Viktorin A, Brown HK, Di Florio A, D’Onofrio BM, et al. Maternal and infant outcomes associated with lithium use in pregnancy: an international collaborative meta-analysis of six cohort studies. Lancet Psychiatry. (2018) 5:644–52. doi: 10.1016/S2215-0366(18)30180-9

Environmental Risk Factors and CHD

Zhang et al.
53. Nieuwenhuisen MJ, Martinez D, Grellier J, Bennett J, Best N, Iszatt N, et al. Chlorination disinfection by-products in drinking water and congenital anomalies: review and meta-analyses. Environ Health Perspect. (2009) 117:1486–93. doi: 10.1289/ehp.0900677

54. Browne ML. Maternal exposure to caffeine and risk of congenital anomalies: a systematic review. Epidemiology. (2006) 17:324–31. doi: 10.1097/01.ede.0000208476.36988.44

55. Spinder N, Prins JR, Bergman JEH, Smidt N, Kromhout H, Boezen HM, et al. Congenital heart defects in monozygotic twins: a systematic review and meta-analysis. Ultrasound Obstet Gynecol. (2018) 51:33–42. doi: 10.1002/uog.18932

56. Feng Y, Wang S, Zhao L, Yu D, Hu L, Mo X. Maternal reproductive history and the risk of congenital heart defects in offspring: a systematic review and meta-analysis. Pediatr Cardiol. (2015) 36:253–63. doi: 10.1007/s00246-014-1079-z

57. Feng Y, Yu D, Chen T, Liu J, Tong X, Yang L, et al. Maternal parity and the risk of congenital heart defects in offspring: a dose-response meta-analysis of epidemiological observational studies. PLoS ONE. (2014) 9:e108944. doi: 10.1371/journal.pone.0108944

58. Giorgione V, Parazzini F, Fesslova V, Cipriani S, Candiani M, Inversetti A, et al. Congenital heart defects in IVF/ICSI pregnancy: systematic review and meta-analysis. Ultrasound Obstet Gynecol. (2018) 51:33–42. doi: 10.1002/uog.18932

59. Girlanda M, Belbasis L, Tzoulaki I, Evangelou E, Ioannidis JP. Environmental risk factors and Parkinson’s disease: an umbrella review of meta-analyses. Parkinsonism Relat Disord. (2016) 23:1–9. doi: 10.1016/j.parkreldis.2015.12.008

60. Jarvie E, Hauguel-de-Mouzon S, Nelson SM, Sattar N, Catalano PM, Shankar K. Obesity and pregnancy: mechanisms of short term and long term adverse consequences for mother and child. BMJ. (2017) 356:j1. doi: 10.1136/bmj.j1

61. Persson M, Norman M, Hanson U. Obstetric and perinatal outcomes in type 1 diabetic pregnancies: a large, population-based study. Diabetes Care. (2009) 32:2005–9. doi: 10.2337/dc09-0656

62. Sari Y, Zhou PC. Serotonin and its transporter on proliferation of fetal heart cells. Int J Dev Neurosci. (2003) 21:417–24. doi: 10.1016/j.devneu.2003.10.002

63. Guan J, Mao C, Xu F, Zhu L, Liu Y, Geng C, et al. Low doses of nicotine-induced fetal cardiovascular responses, hypoxia, and brain cellular activation in ovine fetuses. Neurotoxicology. (2009) 30:290–7. doi: 10.1016/j.neuro.2008.12.013

64. Clark EB. Pathogenetic mechanisms of congenital cardiovascular malformations revisited. Semin Perinatol. (1996) 20:465–72. doi: 10.1016/S0166-4328(00)80062-0

65. Puscheck EE, Jeyendran RS. The impact of male factor on recurrent pregnancy loss. Curr Opin Obstet Gynecol. (2007) 19:222–8. doi: 10.1097/GCO.0b013e328133f8b0

66. Correa A, Levis DM, Tinker SC, Cragan JD. Maternal cigarette smoking and congenital heart defects. J Pediatr. (2015) 166:801–4. doi: 10.1016/j.jpeds.2015.01.013

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Zhang, Wu, Liu, Lv, Sun, Chang, Liu and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.